Neutralization of recent SARS-CoV-2 variants by genetically and structurally related mAbs of the pemivibart lineage
Pemivibart is a monoclonal antibody therapy currently under Emergency Use Authorization for the for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents over 12 years of age with certain immunocompromised conditions. As a part of the overall monitoring strate...
